Quoth the Raven
· QTR’s Fringe Finance
· 22 июня 2026, 13:23
· ⏱ 3 мин чтения
| Читать в Substack ↗
Резюме
The author celebrates a 200% YTD gain in Definium Therapeutics (DFTX) after positive Phase 3 data for its LSD-based depression drug, validating his long-standing bullish thesis on psychedelic stocks. He argues that policy momentum from RFK Jr.'s HHS and state-level initiatives are driving a paradigm shift, making the sector asymmetric with potential for rapid repricing or buyouts.
•DFTX is up 200% YTD to ~$40 after positive Phase 3 data for DT120, a single-dose LSD-based depression treatment that met its primary endpoint with symptom reduction as early as one week.
•The author had been pounding the table on psychedelic stocks for years, naming them to his '26 Stocks to Watch for 2026' and calling the sector his 'best idea' for the year.
•RFK Jr.'s Department of Health and Human Services has expedited psychedelic drug approval, part of the administration's executive order supporting research.
•States including Oregon, Colorado, New Mexico, and Texas are funding research and building regulatory frameworks independent of FDA approval, mirroring cannabis's early path.
•The author's core thesis is that psychedelics are not incremental improvements on SSRIs but fundamentally different tools producing durable outcomes in a fraction of the time.
•Risk is not that psychedelics don't work, but missing the window before the rest of the market is forced to catch up; companies need legitimacy, not perfection.
DFTX is a psychedelic stock with positive Phase 3 data for LSD-based depression treatment, up 200% YTD, benefiting from regulatory tailwinds from RFK's HHS.
This newsletter, published June 22, 2026,
features Quoth the Raven
discussing DFTX, CMPS.
2 trade ideas extracted by AI with direction and confidence scoring.